China Life Sciences Newsletter -- April 2012

more+
less-
more+
less-
Explore:  China Life Sciences USPTO

In This Issue:

*Investor Q&A

*Trends and Best Practices in R&D Strategic Partnerships in China

*USPTO Proposed Rules on Preissuance Submissions

Excerpt from Investor Q&A

Interview by Chuck Comey, Dave Chang, and Patrick Fischer

John Oyler is the founder and CEO of BeiGene Ltd., a Beijing-based biotechnology company that focuses on discovering and developing innovative oncology drugs. Few can match Mr. Oyler’s record as a serial founder. He previously founded and was CEO of BioDuro, a 700-person integrated contract research organization (CRO) in Beijing, which was sold to PPD with attractive returns. Mr. Oyler is also the former CEO of Galenea, a Bostonbased biotech spinout from Massachusetts Institute of Technology with funding from Otsuka; the former co-CEO of Genta, a publicly traded oncology company that grew to be worth $1.7 billion; and the former founder and president of Telephia, which was bought by Nielsen. He holds an MBA from Stanford University and a BS from Massachusetts Institute of Technology.

Please see full newsletter below for more information.

LOADING PDF: If there are any problems, click here to download the file.